Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
QuantumPharm, Inc. ( (HK:2228) ) has issued an announcement.
XtalPi Holdings Limited’s subsidiary QuantumPharm Limited has subscribed to a new batch of exchange-rate linked, principal‑guaranteed structured deposits issued by Shanghai Pudong Development Bank, committing RMB356.1 million on 11 September 2025 using idle funds. Aggregated with a series of similar SPDB structured deposits purchased earlier in 2025, the deals meet Hong Kong listing rules thresholds for a discloseable transaction, signaling an active but conservative treasury management strategy that boosts yield on surplus cash without requiring shareholder approval.
The structured products, classified as low risk by the issuing bank, carry terms ranging from 27 to 169 days and offer expected annualised returns generally between 0.7% and 2.2%, reflecting a focus on capital preservation with modest income generation. By concentrating short‑term liquidity in guaranteed principal instruments from a single major bank within a 12‑month window, the group is optimizing cash management while accepting some counterparty concentration risk, a factor investors may monitor as part of its financial risk profile.
More about QuantumPharm, Inc.
XtalPi Holdings Limited, through its subsidiary QuantumPharm Limited, operates in the financial and investment management segment of its broader technology-driven business by deploying idle cash into low-risk wealth management products. The group utilizes structured deposit products from Chinese commercial banks as a treasury tool to enhance returns on surplus funds while preserving capital.
Average Trading Volume: 55,539,899
Technical Sentiment Signal: Hold
Current Market Cap: HK$40.99B
For an in-depth examination of 2228 stock, go to TipRanks’ Overview page.